What is Antimicrobial Resistance (AMR)?
In 2019, the World Health Organisation (WHO) declared that antimicrobial resistance (AMR) is one of the top ten global public health threats facing humanity. Faced with this reality, the need for action to avert a developing global crisis in healthcare is imperative.
The development of innovative new antimicrobial drugs is an essential part of the fight against AMR. However, at present, there is a lack of sufficient incentives for companies to invest in innovative antimicrobials, as there have traditionally been high costs and low returns associated with their R&D. The UK is leading the charge in tackling this global issue, including by implementing new reimbursement models to incentivise investment in new treatments, and supporting new funding streams for the development of innovative drugs and diagnostics.
There a number of UK biotech companies working in the antimicrobial space, and the BIA works with these companies to highlight the importance of research into novel antimicrobials, and encourage further investment in this space.
Recent activity in AMR
AMR Publications
World Antimicrobial Awareness Week (WAAW)
WAAW is a global campaign celebrated annually to improve awareness and understanding of AMR. We've collaborated with SwedenBIO and the International Council of Biotechnology Associations (ICBA) to launch a campaign to spread awareness and eradicate #TheSilentPandemic. Read this blog to understand why tackling AMR is imperative for the future of medical innovation.